Alnylam Pharma (ALNY) Tops Q4 EPS by 19c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $288.18 +0.62%
EPS Growth %: +409.4%
Financial Fact:
Total other income (expense): 2.32M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: +409.4%
Financial Fact:
Total other income (expense): 2.32M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($2.09), $0.19 better than the analyst estimate of ($2.28). Revenue for the quarter came in at $21.03 million versus the consensus estimate of $15.12 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Cerebras Q1 EPS miss sends shares down 9% after-hours
- Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
